NCT00245362View on ClinicalTrials.gov

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

June 30, 2004

Conditions
Metastatic Pancreatic CancerNonresectable Pancreatic Cancer
Interventions
BIOLOGICAL

CG 8020 and CG 2505

Trial Locations (2)

Unknown

Johns Hopkins University School of Medicine, Baltimore

US Oncology, Dallas

Sponsors

Lead Sponsor

Cell Genesys
All Listed Sponsors
lead

Cell Genesys

INDUSTRY

NCT00245362 - A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter